ProHealing Drug Alternative for Coronary Drug Eluting Stents

冠状动脉药物洗脱支架的 ProHealing 药物替代品

基本信息

  • 批准号:
    8392045
  • 负责人:
  • 金额:
    $ 19.77万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2012
  • 资助国家:
    美国
  • 起止时间:
    2012-08-15 至 2014-07-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): ProHealing Drug Alternative for Coronary Drug Eluting Stents Our goal is to develop a novel, safer and more efficacious approach for treating Coronary Artery Disease, by incorporating a modulator of growth factor activity, PRM-100, within a Drug Eluting Stent (DES). Current DES elute anti-neoplastic (i.e. cytostatic or cytotoxic) agents to block the expansion of smooth muscle cells (SMC) and thereby prevent restenosis. However, as anti-neoplastics either kill or render endothelial cells at the stent site dysfunctiona for many years, patients face an increasing probability of restenosis with time and are predisposed toward life-threatening thrombotic events (e.g. fatal clots), a side effect that necessitates chronic or indefinite administration of potent Dual Anti-Platelet Therapies (DAPT). Notably, many patients are non-compliant with the DAPT treatment regime; furthermore, those that do comply with DAPT incur significant adverse effects (e.g. 6% major bleeding and 11% minor bleeding complications). To avoid these complications, we propose to replace anti-neoplastics with PRM-100, which works by down-regulating and modulation of growth factor activity, effectively inhibiting growth and proliferation of smooth muscle cells, while remaining non-toxic to endothelial cells. Reestablishment of an intact functional endothelium at the stented site provides a natural anti-thrombotic surface that actively controls arterial wall remodeling to limit restenosis. Our hypothesis is that we can find an optimal therapeutic dose of PRM-100 and effectively apply it with a coating for local delivery from a DES into a coronary artery which will perform better than current DES. To test this hypothesis, we propose the following specific aims: Aim 1. Cell culture studies: Inhibition of smooth muscle cell and effect on endothelial cells by PRM-100. Milestone: Demonstration that PRM-100 effectively inhibits SMC proliferation while also being non-toxic to endothelial cells at a low and achievable dose and concentration [e.g., 5 - 30 ¿g per ml, eluted for up to a 30 day period]. PRM-100 will be compared to drugs currently used on DES, specifically, sirolimus or a sirolimus analogue such as everolimus. Aim 2. In vivo efficacy using a DES platform. Milestone. Improved therapeutic profile as compared to current technology as measured by decreased intimal hyperplasia, improved re-endothelialization, and absence of inflammation in PRM-100-eluting stents compared directly to polymer-only DES, but also indirectly to bare metal stents and other DES. On successful completion of this Phase I SBIR, we will have proof-of-concept for the use of PRM-100 in a drug eluting stent for the treatment of coronary artery disease, and be poised to launch a Phase II SBIR, which will include in-depth pharmacokinetics/dynamics, potentially a fully bioabsorbable stent, GLP Animal Studies and preparation for First-in-Man. PUBLIC HEALTH RELEVANCE: Our goal is to develop a novel approach for treating coronary artery disease, by incorporating a different class of drug, PRM-100, within a Drug Eluting Stent (DES). To avoid the complications that currently occur from the use of the cell-damaging or cell-killing drugs now used in DES, we propose to test PRM- 100, which inhibits growth and proliferation of smooth muscle cells, while remaining non-toxic to endothelial cells, in cell cultue and on metal discs that simulate a stent and also on stents in animal studies. On successful completion of this Phase I SBIR, we will have proof-of-concept for the use of PRM- 100 in a DES for the treatment of coronary artery disease, and be poised to launch a Phase II SBIR, which will allow us to prepare for clinical testing.
描述(由申请人提供):冠状动脉药物洗脱支架的ProHealing药物替代品我们的目标是通过在药物洗脱支架(DES)中加入生长因子活性调节剂PRM-100,开发一种治疗冠状动脉疾病的新型、更安全、更有效的方法。当前DES具有抗肿瘤作用(即细胞抑制或细胞毒性) 阻断平滑肌细胞(SMC)扩张从而防止再狭窄的药物。然而,由于抗肿瘤药物多年来要么杀死支架部位的内皮细胞,要么使其功能障碍,患者面临的再狭窄概率随着时间的推移而增加,并且易于发生危及生命的血栓形成事件(例如致命性血栓),这是一种需要长期或无限期给予强效双重抗血小板治疗(DAPT)的副作用。值得注意的是,许多患者不依从DAPT治疗方案;此外,那些依从DAPT的患者会产生显著的不良反应(例如,6%的大出血和11%的轻微出血并发症)。为了避免这些并发症,我们建议用PRM-100代替抗肿瘤药物,PRM-100通过下调和调节生长因子活性,有效抑制平滑肌细胞的生长和增殖,同时保持对内皮细胞无毒。在支架植入部位重建完整的功能性内皮提供了一个天然的抗血栓形成表面,可主动控制动脉壁重塑,以限制再狭窄。我们的假设是,我们可以找到PRM-100的最佳治疗剂量,并将其与涂层一起有效地应用于从DES局部递送到冠状动脉中, 比当前的DES性能更好。为了验证这一假设,我们提出了以下具体目标:目标1。细胞培养研究:平滑肌细胞抑制和对内皮细胞的影响 PRM-100里程碑:证明PRM-100在低且可实现的剂量和浓度下有效地抑制SMC增殖,同时对内皮细胞也是无毒的[例如,5 - 30 μ g/ml,洗脱长达30天]。PRM-100将与目前用于DES的药物进行比较,特别是西罗莫司或西罗莫司类似物,如依维莫司。目标2.使用DES平台的体内疗效。里程碑与当前技术相比,通过与仅含聚合物的DES直接比较,以及与裸金属支架和其他DES间接比较,PRM-100洗脱支架的内膜增生减少、再内皮化改善和无炎症来测量治疗特征改善。 成功完成I期SBIR后,我们将对PRM-100用于治疗冠状动脉疾病的药物洗脱支架进行概念验证,并准备启动II期SBIR,其中将包括深入的药代动力学/动力学,可能是完全生物可吸收的支架,GLP动物研究和首次人体试验的准备。 公共卫生关系:我们的目标是通过在药物洗脱支架(DES)中加入不同类型的药物PRM-100,开发一种治疗冠状动脉疾病的新方法。为了避免目前在DES中使用的细胞损伤或细胞杀伤药物的并发症,我们建议在细胞培养物和模拟支架的金属圆盘以及动物研究中的支架上测试PRM- 100,其抑制平滑肌细胞的生长和增殖,同时保持对内皮细胞无毒。在成功完成第一阶段SBIR后,我们将对在DES中使用PRM- 100治疗冠状动脉疾病进行概念验证,并准备启动第二阶段SBIR,这将使我们能够为临床试验做好准备。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Patrick SL Wong其他文献

Patrick SL Wong的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

相似海外基金

SBIR Phase II: Novel size-changing, gadolinium-free contrast agent for magnetic resonance angiography
SBIR II 期:用于磁共振血管造影的新型尺寸变化、无钆造影剂
  • 批准号:
    2322379
  • 财政年份:
    2023
  • 资助金额:
    $ 19.77万
  • 项目类别:
    Cooperative Agreement
ImproviNg rEnal outcomes following coronary angiograPhy and/or percuTaneoUs coroNary intErventions: a pragmatic, adaptive, patient-oriented randomized controlled trial
改善冠状动脉造影和/或经皮冠状动脉介入治疗后的肾脏结局:一项务实、适应性、以患者为导向的随机对照试验
  • 批准号:
    478732
  • 财政年份:
    2023
  • 资助金额:
    $ 19.77万
  • 项目类别:
    Operating Grants
Neonatal Optical Coherence Tomography Angiography to Assess the Effects of Postnatal Exposures on Retinal Development and Predict Neurodevelopmental Outcomes
新生儿光学相干断层扫描血管造影评估产后暴露对视网膜发育的影响并预测神经发育结果
  • 批准号:
    10588086
  • 财政年份:
    2023
  • 资助金额:
    $ 19.77万
  • 项目类别:
Motion-Resistant Background Subtraction Angiography with Deep Learning: Real-Time, Edge Hardware Implementation and Product Development
具有深度学习的抗运动背景减影血管造影:实时、边缘硬件实施和产品开发
  • 批准号:
    10602275
  • 财政年份:
    2023
  • 资助金额:
    $ 19.77万
  • 项目类别:
Highly Accelerated Magnetic Resonance Angiography using Deep Learning
使用深度学习的高加速磁共振血管造影
  • 批准号:
    2886357
  • 财政年份:
    2023
  • 资助金额:
    $ 19.77万
  • 项目类别:
    Studentship
Development of a method to simultaneously obtain cerebral blood flow information and progression of cerebral white matter lesions using head MR angiography.
开发一种使用头部磁共振血管造影同时获取脑血流信息和脑白质病变进展的方法。
  • 批准号:
    23K14839
  • 财政年份:
    2023
  • 资助金额:
    $ 19.77万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Development of a new diagnostic method for coronary artery disease using automated image analysis with postmortem coronary angiography CT
使用死后冠状动脉造影 CT 自动图像分析开发冠状动脉疾病的新诊断方法
  • 批准号:
    23K19795
  • 财政年份:
    2023
  • 资助金额:
    $ 19.77万
  • 项目类别:
    Grant-in-Aid for Research Activity Start-up
Novel ultrahigh speed swept source OCT angiography methods in diabetic retinopathy
糖尿病视网膜病变的新型超高速扫源 OCT 血管造影方法
  • 批准号:
    10656644
  • 财政年份:
    2023
  • 资助金额:
    $ 19.77万
  • 项目类别:
Automated Machine Learning-Based Brain Artery Segmentation, Anatomical Prior Labeling, and Feature Extraction on MR Angiography
基于自动机器学习的脑动脉分割、解剖先验标记和 MR 血管造影特征提取
  • 批准号:
    10759721
  • 财政年份:
    2023
  • 资助金额:
    $ 19.77万
  • 项目类别:
SCH: A physics-informed machine learning approach to dynamic blood flow analysis from static subtraction computed tomographic angiography imaging
SCH:一种基于物理的机器学习方法,用于从静态减影计算机断层血管造影成像中进行动态血流分析
  • 批准号:
    2205265
  • 财政年份:
    2022
  • 资助金额:
    $ 19.77万
  • 项目类别:
    Standard Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了